Recursion stock jumps as J.P. Morgan upgrades (RXRX:NASDAQ)

Core Insights - Recursion Pharmaceuticals (RXRX) saw an approximately 11% increase in morning trading on Wednesday following an upgrade by J.P. Morgan from Neutral to Overweight, highlighting the significant sales potential of its lead asset, REC-4881 [2] Company Summary - J.P. Morgan analyst Priyanka Grover emphasized the blockbuster sales potential for REC-4881, indicating strong market expectations for the product [2]